Comparative safety study of carboplatin desensitization therapy and cisplatin desensitization therapy in cases of carboplatin hypersensitivity

Abstract

Synopsis: Platinum drugs are key drugs for gynecological malignancies, but as the frequency of administration increases, hypersensitivity, especially to carboplatin (CBDCA), increases. In the present study, we compared the safety of CBDCA and CDDP desensitization therapy in patients with a history of hypersensitivity to CBDCA. All 14 patients with a history of CBDCA hypersensitivity were treated with 38 CBDCA desensitization sessions and 30 CDDP desensitization session, with completion rates of 86.8%and 100%, respectively. No recurrent hypersensitivity was observed after CDDP desensitization therapy. In gynecologic malignancies, limitation of platinum dosing due to CBDCA hypersensitivity may lead to markedly worse prognosis. Although safety precautions must be taken, the pharmacologic mechanism of action suggests that CDDP desensitization therapy may be useful in the treatment of CBDCA hypersensitivity.Key words: cisplatin, carboplatin, desensitization, hypersensitivity